MX2020005370A - Prevencion y tratamiento de enfermedad de injerto contra hospedero con defensinas. - Google Patents
Prevencion y tratamiento de enfermedad de injerto contra hospedero con defensinas.Info
- Publication number
- MX2020005370A MX2020005370A MX2020005370A MX2020005370A MX2020005370A MX 2020005370 A MX2020005370 A MX 2020005370A MX 2020005370 A MX2020005370 A MX 2020005370A MX 2020005370 A MX2020005370 A MX 2020005370A MX 2020005370 A MX2020005370 A MX 2020005370A
- Authority
- MX
- Mexico
- Prior art keywords
- prevention
- treatment
- gvhd
- defensins
- versus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17203527 | 2017-11-24 | ||
| EP18191954 | 2018-08-31 | ||
| PCT/EP2018/082022 WO2019101773A2 (en) | 2017-11-24 | 2018-11-21 | Prevention and treatment of graft-versus-host-disease with defensins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020005370A true MX2020005370A (es) | 2020-10-19 |
Family
ID=64308771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020005370A MX2020005370A (es) | 2017-11-24 | 2018-11-21 | Prevencion y tratamiento de enfermedad de injerto contra hospedero con defensinas. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20200291082A1 (https=) |
| EP (1) | EP3713590B1 (https=) |
| JP (1) | JP7423523B2 (https=) |
| KR (1) | KR20200097251A (https=) |
| CN (1) | CN111741762A (https=) |
| AU (1) | AU2018371948A1 (https=) |
| BR (1) | BR112020010180A2 (https=) |
| CA (1) | CA3083315A1 (https=) |
| ES (1) | ES3038390T3 (https=) |
| MX (1) | MX2020005370A (https=) |
| PL (1) | PL3713590T3 (https=) |
| RU (1) | RU2020116903A (https=) |
| SG (1) | SG11202004207VA (https=) |
| WO (1) | WO2019101773A2 (https=) |
| ZA (1) | ZA202002669B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102244161B1 (ko) * | 2018-08-31 | 2021-04-26 | 주식회사 나이벡 | 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도 |
| KR20230112561A (ko) * | 2022-01-20 | 2023-07-27 | 가톨릭대학교 산학협력단 | 간이식환자 장내균총 분석과 이를 통한 이식상태 모니터링과 면역조절 테라그노시스 조성물 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| DE4343591A1 (de) | 1993-12-21 | 1995-06-22 | Evotec Biosystems Gmbh | Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| NZ540506A (en) * | 2002-12-19 | 2008-09-26 | Yitzchak Hillman | Disease treatment via antimicrobial peptide inhibitors |
| AU2009209565B2 (en) | 2008-02-01 | 2013-09-19 | Ascendis Pharma As | Prodrug comprising a self-cleavable linker |
| WO2009113065A1 (en) * | 2008-03-13 | 2009-09-17 | Hadasit Medical Research Services & Development Ltd. | Immuno-modulating compositions for the treatment of immune-mediated disorders |
| SG172709A1 (en) | 2008-07-18 | 2011-07-28 | Novozymes Adenium Biotech As | Treatment of inflammatory bowel diseases with mammal beta defensins |
| KR101722961B1 (ko) | 2009-02-11 | 2017-04-04 | 알부메딕스 에이/에스 | 알부민 변이체 및 접합체 |
| JP6219277B2 (ja) * | 2011-07-08 | 2017-10-25 | ディフェンシン セラピューティクス アンパルトセルスカブＤｅｆｅｎｓｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ａｐｓ | 炎症性腸疾患の経口治療 |
| WO2016086161A1 (en) * | 2014-11-25 | 2016-06-02 | Memorial Sloan-Kettering Cancer Center | Intestinal microbiota and gvhd |
| CN104971343B (zh) * | 2015-07-13 | 2018-02-02 | 韩源平 | 防御素在制备治疗代谢综合征药物方面的应用 |
| BR112018015170A2 (pt) * | 2016-01-26 | 2018-12-18 | Defensin Therapeutics Aps | métodos para tratamento de doenças, para promoção de crescimento magro, para tratamento ou normalização de uma microbiota disbiótica no intestino, para aumentar riqueza gênica da microbiota intestinal, para aumentar número de filos da microbiota intestinal, para aumentar produção de ácidos graxos de cadeia curta da microbiota intestinal/metaboloma, para aumentar número de bactérias, para diminuir número de bactérias, defensina a, defensina ss, ou um fragmento bioativo das mesmas, e, defensina a e/ou defensina ss e/ou um glp-1/análogo de glp-1. |
| MX2020004863A (es) * | 2017-11-10 | 2020-10-14 | Defensin Therapeutics Aps | Maduracion de la defensa de la mucosa y/o funcion intestinal/pulmonar en el bebe prematuro. |
-
2018
- 2018-11-21 PL PL18803442.5T patent/PL3713590T3/pl unknown
- 2018-11-21 EP EP18803442.5A patent/EP3713590B1/en active Active
- 2018-11-21 WO PCT/EP2018/082022 patent/WO2019101773A2/en not_active Ceased
- 2018-11-21 BR BR112020010180-0A patent/BR112020010180A2/pt not_active IP Right Cessation
- 2018-11-21 RU RU2020116903A patent/RU2020116903A/ru unknown
- 2018-11-21 AU AU2018371948A patent/AU2018371948A1/en not_active Abandoned
- 2018-11-21 JP JP2020528244A patent/JP7423523B2/ja active Active
- 2018-11-21 CN CN201880076137.1A patent/CN111741762A/zh active Pending
- 2018-11-21 US US16/765,746 patent/US20200291082A1/en not_active Abandoned
- 2018-11-21 CA CA3083315A patent/CA3083315A1/en active Pending
- 2018-11-21 KR KR1020207015412A patent/KR20200097251A/ko not_active Ceased
- 2018-11-21 ES ES18803442T patent/ES3038390T3/es active Active
- 2018-11-21 MX MX2020005370A patent/MX2020005370A/es unknown
- 2018-11-21 SG SG11202004207VA patent/SG11202004207VA/en unknown
-
2020
- 2020-05-12 ZA ZA2020/02669A patent/ZA202002669B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200097251A (ko) | 2020-08-18 |
| JP2021504348A (ja) | 2021-02-15 |
| PL3713590T3 (pl) | 2025-09-15 |
| RU2020116903A3 (https=) | 2022-04-08 |
| SG11202004207VA (en) | 2020-06-29 |
| CA3083315A1 (en) | 2019-05-31 |
| WO2019101773A2 (en) | 2019-05-31 |
| WO2019101773A3 (en) | 2019-07-04 |
| AU2018371948A1 (en) | 2020-06-11 |
| EP3713590C0 (en) | 2025-05-07 |
| ES3038390T3 (en) | 2025-10-13 |
| CN111741762A (zh) | 2020-10-02 |
| RU2020116903A (ru) | 2021-12-24 |
| US20200291082A1 (en) | 2020-09-17 |
| EP3713590B1 (en) | 2025-05-07 |
| ZA202002669B (en) | 2021-05-26 |
| JP7423523B2 (ja) | 2024-01-29 |
| EP3713590A2 (en) | 2020-09-30 |
| BR112020010180A2 (pt) | 2021-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY155137A (en) | Compounds that expand hematopoietic stem cells | |
| WO2012069568A3 (en) | Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination | |
| TN2013000427A1 (en) | Modified acid alpha glucosidase with accelerated processing | |
| MX2018004616A (es) | Cosmetica qie tiene bacterias probioticas. | |
| HK1252778A1 (zh) | 细胞扩增方法和治疗组合物 | |
| MX2020005370A (es) | Prevencion y tratamiento de enfermedad de injerto contra hospedero con defensinas. | |
| WO2019098759A3 (ko) | 형질전환된 인간세포 및 이의 용도 | |
| WO2016030644A3 (fr) | Procédé d'induction de la synthèse des phycobiliproteines | |
| MX2015017257A (es) | Composiciones y metodos de inmunizar contra clostridium difficile. | |
| JP2015517520A5 (https=) | ||
| MY167069A (en) | Antigen peptide and use thereof | |
| WO2021015615A8 (en) | Low density cell culture | |
| MX2020002552A (es) | Métodos y composiciones para preparar proteína surfactante d (sp-d). | |
| IN2014DN05784A (https=) | ||
| TW201613621A (en) | Composition for promoting growth of dermal papilla cells, pharmaceutical composition, and preparation method thereof | |
| Lladó | Sedation for endoscopy in 2016-Is endoscopist-guided sedation safe in complex situations? | |
| Wang et al. | High dose lipopolysaccharide triggers polarization of mouse thymic Th17 cells in vitro in the presence of mature dendritic cells | |
| Liu et al. | IL33 and TNFα synergistically enhance store operated Ca2+ entry in cultured human airway smooth muscle cells | |
| ZHANG et al. | Evaluation of the function of autotransplanted parathyroid tissues | |
| Lyamina et al. | Imbalance of M1/M2 alveolar macrophages phenotype in pulmonary sarcodosis | |
| Shin | The beneficial effect of leflunomide on systemic lupus erythematosus: the role of Tregs repopulation? Comment on: Leflunomide: friend or foe for systemic lupus erythematosus? Rheumatol Int 2013, 33 (2): 273–6 | |
| Hansson et al. | Macrophages Sources Of IL-22 Protein In Mouse Lungs Exposed To Peptidoglycan Or IL-23 | |
| Suzuki et al. | Technique of Harmonic Focus In Tracheostomy | |
| LT2014112A (lt) | Iš normalių audinių gautos ksenogeninės vakcinos, skirtos pažeisti imuninės sistemos su navikais susijusių antigenų toleravimą | |
| Бенин | Technicus, humanitas et cultura |